Arcturus Therapeutics Logo
US03969T1097
A2PMAS
ARCT

Arcturus Therapeutics

Prognose

Analytikernes gennemsnitlige kursmål er 27,80 € (+309,43 %). Medianen er 27,80 € (+309,43 %).

Køb
  12
Behold
  5
Sælg
  4

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Arcturus Therapeutics presents pipeline at Cantor conference; pivotal data expected soon

    Arcturus Therapeutics presented three core programs at the Cantor Global Healthcare Conference: ARCT-810 for OTC deficiency, an inhaled mRNA program for cystic fibrosis (CF), and a self-amplifying mRNA platform with commercial vaccine success. Near-term catalysts include the Phase II readout for ARCT-810 expected later this month, FDA feedback, and a fourth-quarter decision on whether to continue the CF program — a move that could trigger funding from Thermo Fisher. Management highlights technological advantages (biodegradable LNPs, improved mRNA purification, a tailored nebulizer) but still sees risks around efficacy, safety and competition. » Mere på de.investing.com


  • Arcturus Therapeutics sees 2026 as a turning point with two near-term catalysts

    At the Citigroup conference, Arcturus Therapeutics announced two near-term catalysts: Phase II data on OTC deficiency in September and a go/no-go decision on initiating Phase III for cystic fibrosis in the fourth quarter. The inhaled mRNA platform was presented as differentiated after safety and tolerability issues were addressed. Thermo Fisher has committed up to $40 million to non-dilutively support the Phase III cystic fibrosis development in exchange for exclusive manufacturing rights. The vaccine business provides non-dilutive revenue to fund the therapeutic pipeline; substantial CF data are expected in early 2025. » Mere på de.investing.com


  • Arcturus Therapeutics jumps after management signal and conference announcements

    Arcturus Therapeutics’ stock rose intraday by about 10–13% after management announced participation in five major investor conferences in September, viewed as a vote of confidence in the pipeline. Key clinical milestones for ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency) are approaching. Analyst support, better-than-expected quarterly results, more than $191 million in cash and a strategic manufacturing agreement with Thermo Fisher bolster the funding outlook through 2028 and the credibility for a potential phase 3 study. The rally occurred despite a weaker broader market and appears to be company-specific. » Mere på de.investing.com


  • Arcturus highlights strong liquidity and upcoming clinical catalysts

    Arcturus has more than $200 million in liquidity, giving it a funding runway into 2028 to support development of its programs. The company expects a Q4 2024 decision on advancing ARCT-032 (inhaled mRNA for cystic fibrosis) into phase III and anticipates data and regulatory guidance for ARCT-810 (OTC deficiency) before Sept. 30, 2024. The vaccine business, including KOSTAIVE (approved in 32 countries), has been returned to 100% strategic control and is intended to help fund the therapeutics pipeline. Arcturus is evaluating partnerships and has outlined a possible $40 million support from Thermo Fisher tied to a phase III decision. » Mere på de.investing.com


  • Arcturus Therapeutics reduces quarterly loss more than expected despite 89% revenue drop

    Arcturus reported an adjusted loss of $0.84 per share in Q2 versus a consensus expectation of $1.05, beating estimates by 20%. Revenue fell to $2.96 million, a decline of 89.4% year‑on‑year after the end of the collaboration with CSL Seqirus. Cash and equivalents amounted to $191.5 million, securing a liquidity runway of more than 2.5 years. The company cut R&D spending, is advancing cystic fibrosis (ARCT‑032) and OTCD (ARCT‑810) programs, and expects Phase II/III decisions and data in the second half of 2026. » Mere på de.investing.com

I 2012 har Arcturus Therapeutics allerede udloddet 2,66 € i udbytte. Den seneste udlodning fandt sted i december 2012.

Virksomhedstal

I det seneste kvartal havde Arcturus Therapeutics en omsætning på 16,15 mio. € og et nettoresultat på -6,55 mio. €

(EUR) september 2026
YoY
Omsætning 16,15 mio. 10,53 %
Bruttofortjeneste 16,15 mio. 37,28 %
Nettoresultat -6,55 mio. 42,88 %
EBITDA -6,55 mio. 39,45 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
211,19 mio. €
Antal aktier
28,82 mio.
Højeste/laveste i 52 uger
16,37 € - 5,01 €
Udbytte Nej
Beta
2,61
P/E (PE Ratio)
-2,59
PEG (PEG Ratio)
0,10
K/I (PB Ratio)
1,36
P/S (PS Ratio)
9,29

Virksomhedsprofil

Arcturus Therapeutics Holdings Inc. er et virksomhed inden for RNA-medicin, der fokuserer på udviklingen af vacciner mod infektionssygdomme samt sjældne leversygdomme og luftvejssygdomme i USA. Virksomhedens udviklingsprogrammer omfatter LUNAR-OTC-udviklingsprogrammet til ornithintranscarbamylase (OTC)-mangel; og LUNAR-CF-programmet til cystisk fibrose-lungesygdom forårsaget af mutationer i genet for cystic fibrosis transmembrane conductance regulator (CFTR), ligesom vaccineprogrammer omfatter LUNAR-COV19 og LUNAR-FLU. Virksomheden har samarbejdspartnerskaber med Vinbiocare Biotechnology Joint Stock Company om fremstilling af COVID-19-vacciner; Janssen Pharmaceuticals, Inc. om udvikling af nukleinsyrebaserede terapeutiske kandidater til behandling af hepatitis B-virus; Ultragenyx Pharmaceutical, Inc. om udvikling af mRNA-terapeutiske kandidater til mål for sjældne sygdomme; CureVac AG om udvikling af mRNA-terapeutiske og vaccinekandidater til forskellige indikationer; Singapore Economic Development Board og Duke-NUS Medical School om udvikling af LUNAR-COV19-vaccinen; og Millennium Pharmaceuticals, Inc. om opdagelse af siRNA-medicin til behandling af non-alkoholisk steatohepatitis. Virksomheden blev grundlagt i 2013 og har hovedkontor i San Diego, Californien.

Navn
Arcturus Therapeutics
CEO
Joseph E. Payne
Hjemsted San Diego, ca
USA
Websted
Sektor
Materialer
Branche
Kemikalier
Børsnotering
22.05.2013
Medarbejdere 109

Tickersymboler

Børs Symbol
NASDAQ
ARCT
🍪

Parqet  bruger cookies. Læs mere